Health
Genethon develops gene therapy for treating Duchenne muscular dystrophy – News-Medical.net
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM,…
Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines and Health Products Safety, to start in France a multicentre international clinical trial for the treatment of Duchenne muscular dystrophy with product GNT 004.
This trial’s goal is to assess the safety and efficacy of an innovative gene therapy designed at Genethon, combining an AAV-type viral vector…
-
Noosa News23 hours agoMajor flood arrives at Birdsville
-
Business8 hours agoHow I’d build a $100,000 ASX portfolio from scratch
-
General21 hours agoTrump’s tariffs: a bad idea executed badly
-
General2 hours agoTony Armstrong and Courtney Act revealed as hosts of Australia’s 2025 Eurovision coverage